Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Garcia Campelo R, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R.
Remon J, et al. Among authors: robinet g.
Ann Oncol. 2023 May;34(5):468-476. doi: 10.1016/j.annonc.2023.02.012. Epub 2023 Feb 28.
Ann Oncol. 2023.
PMID: 36863484
Free article.
Clinical Trial.